Accuray (ARAY)
(Delayed Data from NSDQ)
$1.77 USD
+0.20 (12.74%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.78 +0.01 (0.56%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.77 USD
+0.20 (12.74%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.78 +0.01 (0.56%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth F Momentum C VGM
Zacks News
Accuray (ARAY) Down 13.7% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for May 23rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for May 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for May 9th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Accuray (ARAY) Q3 Loss Wider Than Estimates, Revenues Top
by Zacks Equity Research
Radixact System and major software overhaul drive Accuray (ARAY) in Q3.
Accuray Radixact Picked by India's Apollo for Cancer Treatment
by Zacks Equity Research
Accuray's (ARAY) flagship Radixact radiotherapy platform to help in cancer treatment at Apollo Hospital Group in New Delhi and Chennai, India.
Accuray's CyberKnife Treats First Patient at Erasmus MC
by Zacks Equity Research
Accuray (ARAY) and Erasmus MC partner to develop CyberKnife platform to simplify diagnosis of oligometastatic diseases.
Accuray Banks on Acquisition & Partnership Amid Competition
by Zacks Equity Research
Accuray's (ARAY) partnerships with Premier and Amerinet are expected to help the company gain significant penetration in hospitals and oncology centers.
Varian Medical Receives Regulatory Nod for Sirtex Buyout
by Zacks Equity Research
The acquisition of Sirtex will fortify Varian Medical's (VAR) footprint in Australia. The transaction is likely to close in late May 2018.
Here's Why Small-Cap HealthCare ETFs & Stocks Are Good Picks
by Sanghamitra Saha
Two reasons why small-cap healthcare stocks and ETFs could be winners in the coming days.
Accuray Gains on Radixact Unit, Solid Geographical Foothold
by Zacks Equity Research
Radixact and TomoTherapy along with solid global prospects are the key catalysts for Accuray (ARAY).
Cogentix Medical (CGNT) Looks Good: Stock Adds 13.3% in Session
by Zacks Equity Research
The shares of Cogentix Medical (CGNT) rose over 13% yesterday after reports surfaced that the company is going to be acquired by Laborie Medical Technologies.
Why Is Accuray (ARAY) Down 8% Since its Last Earnings Report?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AmerisourceBergen (ABC) Beats on Q1 Earnings, FY18 View Up
by Zacks Equity Research
Strong Growth in Pharmaceutical Distribution Segment and World Courier business drove AmerisourceBergen (ABC) in Q1.
Becton, Dickinson (BDX) Beats on Q1 Earnings, Guidance Solid
by Zacks Equity Research
Strong growth in BD Medical and BD Life sciences segments drove Becton, Dickinson's (BD) top line in Q1.
athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q4
by Zacks Equity Research
Strong growth in Business and Services segment drove athenahealth's (ATHN) top line in Q4.
Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up
by Zacks Equity Research
Pacific Biosciences' (PACB) consumable revenue platform proves a vital growth-driver in Q4. Sales momentum in China remains robust.
Quest Diagnostics (DGX) Tops Q4 Earnings, 2018 View Strong
by Zacks Equity Research
Quest Diagnostics' (DGX) year-over-year revenue improvement in Q4 came on the back of successful execution of its two-point strategy of accelerating growth and driving operational excellence.
Boston Scientific (BSX) Q4 Earnings In Line, Revenues Top
by Zacks Equity Research
In Q4, Boston Scientific (BSX) registers balanced growth across all business lines and geographies.
Conmed (CNMD) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Conmed (CNMD) benefits from impressive general surgery performance and enhanced innovation in Q4.
McKesson (MCK) Beats on Q3 Earnings & Revenues, Ups '18 View
by Zacks Equity Research
Strong Performance in Distribution Solutions segment drives McKesson (MCK) in Q3. An impressive FY18 outlook instills investor's optimism.
Baxter (BAX) Beats on Q4 Earnings & Revenues, '18 View Solid
by Zacks Equity Research
Strong performance in the Hospital Products and Renal Products segments drives Baxter (BAX) in Q4.
IDEXX Laboratories (IDXX) Beats on Q4 Earnings and Revenues
by Zacks Equity Research
IDEXX (IDXX) rides high on strength in CAG business in Q4. A raised guidance buoys optimism.
4 Reasons Why You Should Buy Accuray (ARAY) Stock Right Now
by Zacks Equity Research
Accuray (ARAY) rides high on its Radixact platform and latest software overhaul.
Zacks.com highlights: Accuray, Berkshire Hills Bancorp, A. Schulman, Sysco and Tailored Brands
by Zacks Equity Research
Zacks.com highlights: Accuray, Berkshire Hills Bancorp, A. Schulman, Sysco and Tailored Brands